Differentiated Thyroid Gland CarcinomaNCT07529080
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
A study testing Internet-Based Intervention, Interview and Questionnaire Administration in people with Differentiated Thyroid Gland Carcinoma and Malignant Testicular Neoplasm, run by University of Michigan Rogel Cancer Center at 1 site in United States.
Trial summary
This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial support - to a support tool providing cancer-specific information alone (minus psychosocial… Read more about this study
- Who is it for?
- Ages 20 to 39 years
- Conditions the study is for
- Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm, Melanoma
- What is being tested?
- Internet-Based Intervention, Interview and Questionnaire Administration
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 142 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2026to Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 39 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- PARTICIPANTS RECRUITED FROM SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM (SEER)-GEORGIA: Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment
- PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer), melanoma, or testicular cancer at any stage and reported to the SEER-Georgia registry
- PARTICIPANTS RECRUITED FROM SEER-GEORGIA: 2-10 years after diagnosis with cancer
- PARTICIPANTS RECRUITED FROM SEER-GEORGIA: English speaking (able to read and speak English)
- PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate "not at all" will be told the study is focused on those who experience worry)
- PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Residing in the United States
Show all 12Show fewer
- PARTICIPANTS RECRUITED FROM THYROID CANCER SURVIVORS' ASSOCIATION INC. (THYCA): Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment
- PARTICIPANTS RECRUITED FROM THYCA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer) at any stage
- PARTICIPANTS RECRUITED FROM THYCA: 2-10 years after diagnosis with cancer
- PARTICIPANTS RECRUITED FROM THYCA: English speaking (able to read and speak English)
- PARTICIPANTS RECRUITED FROM THYCA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate "not at all" will be told the study is focused on those who experience worry)
- PARTICIPANTS RECRUITED FROM THYCA: Residing in the United States
Who cannot join
- PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects from certain vulnerable populations will be excluded as appropriate: fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)
- It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman
- PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects that do not meet the inclusion criteria
- PARTICIPANTS RECRUITED FROM THYCA: Subjects from certain vulnerable populations will be excluded as appropriate fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)
- It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman
- PARTICIPANTS RECRUITED FROM THYCA: Subjects that do not meet the inclusion criteria
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109
Megan R. Haymart, MD, 734-615-6745, support@thrivetrack.study
Megan R. Haymart, MD
About this study
Official title: Personalized Cancer Support for Young Adults
This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial support - to a support tool providing cancer-specific information alone (minus psychosocial modules). This tool, called Thrive Track, will be for YA patients aged 20-39 with thyroid, melanoma, or testicular cancer. Young adult survivors frequently experience persistent worry and distress that can interfere with coping and reduce quality of life. They are also particularly vulnerable to the emotional impact of cancer and may not have adequate support to manage these concerns. The enhanced version of Thrive Track includes personalized emotional support content and strategies designed to help patients better manage worry and distress. Adding these emotional support tools may provide greater benefit than survivorship education alone in strengthening young adult survivors' ability to manage their emotional well-being.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm, Melanoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Being tested
- Internet-Based Intervention, Interview, Questionnaire Administration
- Medical subject headings
- Testicular Neoplasms, Melanoma, Adenocarcinoma, Follicular, Thyroid Cancer, Papillary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Internet-Based InterventionOther
Receive access to Thrive Track website with general cancer-specific survivorship care information
Internet-Based InterventionOther
Receive access to Thrive Track website with general cancer-specific survivorship care information in addition to emotional support content
InterviewOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I (Thrive control) | Active comparator | Patients receive access to Thrive Track website with general cancer-specific survivorship care information for up to 3 months. Receives: Other: Internet-Based Intervention; Other: Interview; Other: Questionnaire Administration |
| Arm II (Thrive Track with emotional support) | Experimental | Patients receive access to Thrive Track website with general cancer-specific survivorship care information in addition to emotional support content for up to 3 months. Receives: Other: Internet-Based Intervention; Other: Interview; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cancer related worry
Cancer-related worry will be evaluated using two 8-item validated scales:
- Cancer Worry Scale (CWS)
- An adapted cancer worry scale
Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the two scales between intervention and control subjects at 3 months post intervention. Scores on the CWS scale range from 8 (minimum) to 32 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes.
Scores on the adapted cancer worry scale range from 8 (minimum) to 40 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes.
Measured: 3 months post-enrollment
Cancer related distress
Cancer-related distress will be measured using the National Comprehensive Cancer Network Distress Thermometer.
Scores on the NCCN Distress Thermometer range from 0 (minimum) to 10 (maximum), with lower scores indicating less distress and more favorable outcomes.
Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the distress thermometer between the intervention and control subjects at 3 months post-intervention using two-sample t-tests.
Measured: 3 months post-enrollment
Secondary outcomes (4)
Knowledge about worry self-management
This outcome will be evaluated using a team-developed 4-item scale. Scores on this scale range from 4 (minimum) to 16 (maximum), with higher scores indicating better knowledge about how to self-manage worry and more favorable outcomes.
Measured: 3 months post-enrollment
Confidence/self-efficacy in the ability to self-manage worry
This outcome will be evaluated using an 11-item scale from the Breast Cancer Self Efficacy Scale (BCSE), adapted for all cancers.
Scores on this scale range from 11 (minimum) to 55 (maximum), with higher scores indicating better self efficacy to manage cancer-related worry and more favorable outcomes.
Measured: At 3 months post-enrollment
Resilience
This outcome will be evaluated using a 6-item validated scale, adapted from the Communication and Attitudinal Self-Efficacy Scale (CASE) and the Cancer Control and Outlook Scale.
Scores on this scale range from 6 (minimum) to 30 (maximum), with higher scores indicating better resilience to deal with cancer and more favorable outcomes.
Measured: At 3 months post-enrollment
Ease of tool use
This outcome will be evaluated using a series of 7 questions designed to help understand the participants' experience using the Thrive Track website.
Measured: At 3 months post-enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2026
- Study startDec 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Differentiated Thyroid Gland CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 142 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Megan R Haymart, MD, Principal investigator, University of Michigan Rogel Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07529080
- Sponsor's protocol ID
- UMCC 2025.051
- Other IDs
- NCI-2026-00929, HUM00270736, R34CA286602
- Status last verified
- Oct 2026
- First submitted
- 5 Mar 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: As described in our Data Management and Sharing plan (DMS), all the final data generated from this study will be de-identified and uploaded to the Inter-University Consortium for Political and Social Research (ICPSR). Additionally, the primary outcome results of the study will be reported to ClinicalTrials.gov no later than 1 year after the primary completion date of the trial.